29 / 30
Conclusions…
Cabozantinib improves overall survival, Progression-free survival and objetive response rate in patients
with advanced HCC when compared with placebo after Sorafenib first line….
Clinical benefit similar to Regorafenib, slightly better than Ramucirumab…
Safety profile is acceptable with a low rate of discontinuation rate due to AE…..
Some Grade 3-4 AEs (HTA, diarrhea, AST increase, PPE...) could be difficult to manage...as well as with
Regorafenib.
Ramucirumab safety profile seems more tolerable
Cabozantinib represents a new treatment option for HCC patients after prior sistemic therapy fails….
Patient´s tolerance to Sorafenib, comorbidities and expectatives are essential to chose the STANDAR?
2nd line.......and Immunoterapy is at the Gate!